DNA-encoded Library Technology for Drug Discovery
1st Edition
Published on 21. February 2025
X, 176 pages
978-1-83916-055-4 (ISBN)
Description
DNA-encoded libraries have numerous advantages over traditional screening methods, including easy identification of compounds and the large quantity of compounds that can be screened simultaneously.
This book provides a comprehensive guide to the implementation of DNA-encoded library technology (DELT) in drug discovery for screening and hit validation, illustrated with successful case studies.
A valuable resource for researchers in drug discovery, this book is complete with successful case studies to illustrate the best practice in implementation and operation of DELT.
This book provides a comprehensive guide to the implementation of DNA-encoded library technology (DELT) in drug discovery for screening and hit validation, illustrated with successful case studies.
A valuable resource for researchers in drug discovery, this book is complete with successful case studies to illustrate the best practice in implementation and operation of DELT.
More details
Other editions
Additional editions
Guansai Liu | Casey J. Krusemark | Jin Li
DNA-encoded Library Technology for Drug Discovery
Book
02/2025
1st Edition
Royal Society of Chemistry
€191.50
Shipment within 3-4 weeks
Persons
Editor
HitGen Inc., China
Purdue University, USA
Purdue University, USA
Purdue University, USA
HitGen Inc., China
Dr Jin Li has over 30 years biopharmaceutical experience (at Protherics and AstraZeneca), with senior scientific and leadership roles in early stage research; as well as experience in initiating and leading major collaboration, research and outsourcing programmes. Before founding HitGen, he held Global Director positions of Compound Sciences and Computational Sciences at AstraZeneca. This included responsibility for computational chemistry, computational biology and compound collection enhancement. Dr Li completed his BSc at Sichuan University, and PhD in macromolecular sciences at Aston University. He then completed post-doctoral research in theoretical biochemistry at Manchester University, UK. Dr Li is also a Fellow of the Royal Society of Chemistry.
Dr Jin Li has over 30 years biopharmaceutical experience (at Protherics and AstraZeneca), with senior scientific and leadership roles in early stage research; as well as experience in initiating and leading major collaboration, research and outsourcing programmes. Before founding HitGen, he held Global Director positions of Compound Sciences and Computational Sciences at AstraZeneca. This included responsibility for computational chemistry, computational biology and compound collection enhancement. Dr Li completed his BSc at Sichuan University, and PhD in macromolecular sciences at Aston University. He then completed post-doctoral research in theoretical biochemistry at Manchester University, UK. Dr Li is also a Fellow of the Royal Society of Chemistry.
Content
- Overview of Affinity-based DEL Selections with Select Target Types and Achievements
- Machine Learning with DEL Selection Data and for DEL design
- One bead one compound (OBOC) DELs for Biochemical Screens
- Live cell-based DEL Selections
- On-DNA Medicinal Chemistry: Focused libraries, fragment expansion, and hit optimization
- DELs with Covalent Warheads
- Application of DELs for E3 Ligase Ligand and PROTAC development
- Machine Learning with DEL Selection Data and for DEL design
- One bead one compound (OBOC) DELs for Biochemical Screens
- Live cell-based DEL Selections
- On-DNA Medicinal Chemistry: Focused libraries, fragment expansion, and hit optimization
- DELs with Covalent Warheads
- Application of DELs for E3 Ligase Ligand and PROTAC development
